Navigation Links
Alexza Prices $16.1 Million Registered Direct Offering
Date:5/3/2011

MOUNTAIN VIEW, Calif., May 3, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA), or the Company, today announced that it has entered into a definitive agreement with three institutional investors, including RA Capital Management and Tavistock Life Sciences, to raise approximately $16.1 million in gross proceeds in a registered direct offering through the sale of common stock and warrants.  The Company agreed to sell a total of 11,927,034 units, each unit consisting of (i) one share of common stock and (ii) one warrant to purchase 0.35 of a share of common stock, at a purchase price of $1.35 per unit.  The warrants will be exercisable six months after issuance at $1.755 per share and will expire five years from the date of issuance.  The shares of common stock and warrants are immediately separable and will be issued separately.  

Alexza estimates that net proceeds from the offering will be approximately $15.8 million, after deducting estimated offering expenses.  The Company intends to use the net proceeds from the sale of the securities primarily for general corporate purposes, including regulatory activity, clinical trial, research and development, general and administrative and manufacturing expenses.  

The securities described above are being offered pursuant to a registration statement on Form S3 previously declared effective by the Securities and Exchange Commission on May 20, 2010. The transaction is expected to close on or about May 6, 2011, subject to customary closing conditions.

A copy of the prospectus supplement relating to the offering and the accompanying base prospectus may be obtained by contacting Alexza Pharmaceuticals, Inc., Attention:  Corporate Secretary, 2091 Stierlin Court, Mountain View, California 94043, or by calling (650) 944-7000.  A copy of the prospectus supplement relating to
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Reports 2010 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
2. Alexza to Announce 2010 Year-End Financial Results on Tuesday, March 15, 2011
3. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
4. Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
5. Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
6. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
7. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
8. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
9. Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
10. Alexzas Staccato® Nicotine Licensed to Cypress Bioscience
11. Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Today, the world,s largest and fastest provider ... more transparent, the importance of websites continues to grow ... maxim of "innovation brings progress and changes thinking" will ... The company has long been recognised as an international ... and modern approach, while also repeatedly breaking new ground ...
(Date:6/2/2015)... June 2, 2015  University Hospitals (UH) ... Cleveland area to implant a new miniaturized, ... HF System is the first and only FDA-approved heart failure ... admissions when used by physicians to manage heart failure., ... that is implanted in the pulmonary artery (PA) during a ...
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/d8nj6b/europe ) has announced ... Growth, Trends And Forecasts (2014 - 2019)" report ... Fluoroscopy is expected to grow at a healthy CAGR ... to view the gastrointestinal tract, to direct the movement ... the urinary system, to open narrowed or blocked blood ...
Breaking Medicine Technology:UH Case Medical Center becomes first in region to offer patients a new heart failure monitoring solution 2UH Case Medical Center becomes first in region to offer patients a new heart failure monitoring solution 3European Fluoroscopy Market Report 2014-2019 - Growth, Trends And Forecasts 2
... , EAST HANOVER, N.J. , June 3 ... III study of Afinitor® (everolimus) tablets plus best supportive care ... survival, or time without tumor growth, in patients with advanced ... I n A dvanced N euroendocrine ...
... Today, the U.S. Food and Drug Administration (FDA) released final ... a long-acting beta-agonist (LABA).  This follows the FDA communication on 18 ... changes. , , , ... http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) , , ...
Cached Medicine Technology:Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 2Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 3Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 4Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 5Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 6Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 7FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 2FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 3FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 4FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 5FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 6
(Date:6/3/2015)... panel of independent experts has spent weeks considering the ... awards presented tonight at TU-Automotive Detroit 2015. , Naturally, ... can now be revealed as: , Car Maker of ... aside by taking the coveted Car Maker of the ... of expert judges., Stand out comments included: , ...
(Date:6/3/2015)... PA (PRWEB) June 03, 2015 Sitting ... can cause discomfort in the back, neck, shoulders and/or ... other musculoskeletal injuries. In addition, recent research links sitting ... number of chronic diseases. Fortunately, three inventors from Oakville, ... sit at a desk. , They have developed a ...
(Date:6/3/2015)... NY (PRWEB) June 03, 2015 Acne is ... (“bacne”) can be particularly stubborn to eliminate and hard to ... most common in teens and young adults, in the years ... produce sebum, or oil,” says Jayme Bashian, director and lead ... characteristic pimples, blackheads and cysts of acne are caused by ...
(Date:6/3/2015)... These are challenging and unpredictable times for ... of digital-first business are rewriting the rules for business ... need for traditional businesses to take on a more ... their services. On top of this there is ... start-ups, to bring new innovation and approaches to business. ...
(Date:6/3/2015)... 2015 “ Scanalytics ” was featured ... which features the latest and coolest technology products available ... host of NewsWatch, conducted the review and shared with ... traffic in retail stores. , Tracking statistics in business ... it comes to retail this goes a step beyond ...
Breaking Medicine News(10 mins):Health News:TU-Automotive Awards 2015 winners revealed 2Health News:TU-Automotive Awards 2015 winners revealed 3Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2Health News:Back Acne: Tips for Clearer Summer Skin 2Health News:Back Acne: Tips for Clearer Summer Skin 3Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2Health News:Technology to Analyze Foot Traffic in Retail Stores was featured on NewsWatch Television 2
... March 18 Askesis Development Group, Inc., a ... addictions treatment, and social services markets, is pleased ... and enhanced features are focused on creating a ... a comprehensive electronic medical record (EMR), and streamlined ...
... of certain cytokines spiked during disease stage , , WEDNESDAY, ... recently had the rare opportunity to follow the West ... in a 29-year-old lab worker who had accidentally jabbed ... researchers followed the trajectory of cytokines, a type of ...
... Institute of Technology are opening a new center that ... resonance imaging scanner to further study into the mysteries ... Advanced Brain Imaging, a joint venture of Georgia State ... topics from autism and learning disabilities, to applied physiology, ...
... disease recurrence, death nearly twice that of normal-weight patients ... cancer patients are more likely than non-obese patients to ... say U.S. researchers. , "We identified a subset ... at 12-fold increased risk of lymph node metastasis compared ...
... CEO until Executive Search for Replacement is CompletedPlanned ... 2009 at 4:15 PM ET LIVINGSTON, N.J., ... Board: MLSS), the recognized leader in advanced injection ... the Board, will temporarily assume the post of ...
... 18 The American Academy of Nurse Practitioners (AANP) ... position of AANP Chief Executive Officer, effective March 20, ... FAANP, who will retire after 13 years as CEO ... will continue in her role as Executive Director of ...
Cached Medicine News:Health News:Askesis Development Group, Inc. Launches New Behavioral Health Software for Electronic Medical Records (EMR) and Practice Management 2Health News:Course of West Nile Infection Charted 2Health News:Course of West Nile Infection Charted 3Health News:Georgia State/Georgia Tech Center for Advanced Brain Imaging to expand brain, mind research 2Health News:Obesity Tied to Poor Pancreatic Cancer Surgery Outcomes 2Health News:Milestone Scientific Announces Resignation of CEO 2Health News:Milestone Scientific Announces Resignation of CEO 3Health News:American Academy of Nurse Practitioners Announces New Chief Executive Officer 2
Spectra 3000RS & Spectra 3000RSP are very precise instruments. They have a metal base structure, durable parts for long life use, and they are very easy to use and maintain....
... Series Spectrophotometer is truly ... UV-VIS instrumentation. The latest ... into a radically new ... and performance unprecedented in ...
... the user to quickly and accurately count bacteria ... counting or manual counting. An optional 1.5X auxiliary ... to 3.0X. The adjustable focusing rod allows the ... The lens also rotates a full 360 for ...
The Accucount 2000 is designed to automatically count microscopic objects in a field displaying totals on a highly visible digital readout....
Medicine Products: